- Home
- CRVO
CRVO
CervoMed Inc.
as of 12-05-2025 1:12pm EST
$8.80
$0.26
-2.87%
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Chart Type:
Time Range:
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 89.1M | IPO Year: | N/A |
| Target Price: | $21.50 | AVG Volume (30 days): | 86.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.87 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.80 - $16.94 | Next Earning Date: | 11-10-2025 |
| Revenue: | $6,159,786 | Revenue Growth: | -38.81% |
| Revenue Growth (this year): | -45.96% | Revenue Growth (next year): | -79.06% |
AI-Powered CRVO Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 73.33%
73.33%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of CervoMed Inc. (CRVO)
Winton Matthew
Buy
Chief Commercial and Business
CRVO Nov 18, 2025
Avg Cost/Share
$7.95
Shares
1,500
Total Value
$11,925.00
Owned After
15,000
SEC Form 4
ELDER WILLIAM ROBERT
Buy
CFO, GC & Secretary
CRVO Nov 18, 2025
Avg Cost/Share
$8.32
Shares
2,500
Total Value
$20,800.00
Owned After
12,500
SEC Form 4
Winton Matthew
Buy
Chief Commercial and Business
CRVO Nov 17, 2025
Avg Cost/Share
$8.43
Shares
3,500
Total Value
$29,505.00
Owned After
15,000
SEC Form 4
Gregoire Sylvie
Buy
Director, 10% Owner
CRVO Nov 17, 2025
Avg Cost/Share
$8.46
Shares
21,600
Total Value
$182,736.00
Owned After
1,484,078
ALAM JOHN J
Buy
CEO & President
CRVO Nov 17, 2025
Avg Cost/Share
$8.46
Shares
21,600
Total Value
$182,736.00
Owned After
12,500
ELDER WILLIAM ROBERT
Buy
CFO, GC & Secretary
CRVO Nov 17, 2025
Avg Cost/Share
$8.45
Shares
1,000
Total Value
$8,450.00
Owned After
12,500
SEC Form 4
Winton Matthew
Buy
Chief Commercial and Business
CRVO Nov 14, 2025
Avg Cost/Share
$7.57
Shares
10,000
Total Value
$75,700.00
Owned After
15,000
SEC Form 4
Gregoire Sylvie
Buy
Director, 10% Owner
CRVO Nov 14, 2025
Avg Cost/Share
$7.56
Shares
3,400
Total Value
$25,704.14
Owned After
1,484,078
ALAM JOHN J
Buy
CEO & President
CRVO Nov 14, 2025
Avg Cost/Share
$7.56
Shares
3,400
Total Value
$25,704.14
Owned After
12,500
Gregoire Sylvie
Buy
Director, 10% Owner
CRVO Nov 13, 2025
Avg Cost/Share
$7.51
Shares
4,447
Total Value
$33,396.97
Owned After
1,484,078
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Winton Matthew | CRVO | Chief Commercial and Business | Nov 18, 2025 | Buy | $7.95 | 1,500 | $11,925.00 | 15,000 | |
| ELDER WILLIAM ROBERT | CRVO | CFO, GC & Secretary | Nov 18, 2025 | Buy | $8.32 | 2,500 | $20,800.00 | 12,500 | |
| Winton Matthew | CRVO | Chief Commercial and Business | Nov 17, 2025 | Buy | $8.43 | 3,500 | $29,505.00 | 15,000 | |
| Gregoire Sylvie | CRVO | Director, 10% Owner | Nov 17, 2025 | Buy | $8.46 | 21,600 | $182,736.00 | 1,484,078 | |
| ALAM JOHN J | CRVO | CEO & President | Nov 17, 2025 | Buy | $8.46 | 21,600 | $182,736.00 | 12,500 | |
| ELDER WILLIAM ROBERT | CRVO | CFO, GC & Secretary | Nov 17, 2025 | Buy | $8.45 | 1,000 | $8,450.00 | 12,500 | |
| Winton Matthew | CRVO | Chief Commercial and Business | Nov 14, 2025 | Buy | $7.57 | 10,000 | $75,700.00 | 15,000 | |
| Gregoire Sylvie | CRVO | Director, 10% Owner | Nov 14, 2025 | Buy | $7.56 | 3,400 | $25,704.14 | 1,484,078 | |
| ALAM JOHN J | CRVO | CEO & President | Nov 14, 2025 | Buy | $7.56 | 3,400 | $25,704.14 | 12,500 | |
| Gregoire Sylvie | CRVO | Director, 10% Owner | Nov 13, 2025 | Buy | $7.51 | 4,447 | $33,396.97 | 1,484,078 |
Latest CervoMed Inc. News
CRVO Breaking Stock News: Dive into CRVO Ticker-Specific Updates for Smart Investing
GlobeNewswire
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)
📈
AI Sentiment
Highly Positive
8/10
Compare CRVO vs Leading Stocks
See how CRVO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CRVO CervoMed Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.